205.25
0.81%
-1.67
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Statement on the Passing of Dr. Stephen Harrison
GlobeNewswire Inc.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
2 Under-the-Radar Growth Stocks to Consider
The Motley Fool
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
The Motley Fool
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
1 No-Brainer Growth Stock to Buy Now
The Motley Fool
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
Zacks Investment Research
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
The Motley Fool
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
The Motley Fool
2 Top Biotech Buyout Candidates
Zacks Investment Research
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
The Motley Fool
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
The Motley Fool
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire Inc.
Madrigal Pharmaceuticals Announces Proposed Public Offering
GlobeNewswire Inc.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Benzinga
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Zacks Investment Research
Madrigal’s stock surges as FDA approves first drug for liver disease MASH
MarketWatch
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga
Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH
MarketWatch
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
GlobeNewswire Inc.
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Zacks Investment Research
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
The Motley Fool
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Rare Stock Picks In February 2024 - From 32 Discerning Analysts
Seeking Alpha
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
The Motley Fool
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
GlobeNewswire Inc.
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
The Motley Fool
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade)
Seeking Alpha
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Eli Lilly’s quarterly results top estimates as obesity, diabetes drugs gain insurance coverage
MarketWatch
'The cautionary signals are off the charts.' Market correction warnings appear
MarketWatch
'The cautionary signals are off the charts.' Market correction warnings appear
MarketWatch
'The cautionary signals are off the charts.' Market correction warnings appear
MarketWatch
2 Rising Biotechs That Could Become the Next Novo Nordisk
The Motley Fool
2 Stocks That Could Soar This Year: Are They Buys?
The Motley Fool
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
Benzinga
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
GlobeNewswire Inc.
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
3 Stocks That Could Be Monster Winners in 2024
The Motley Fool
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
These 2 Stocks Could Be About to Soar: Are They Buys?
The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
The Motley Fool
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
Benzinga
Kapitalisierung:
|
Volumen (24h):